CureApp and its “Digital Therapeutics”, together with NASH (Non-Alcoholic Steatohepatitis) have launched multi-center clinical trials of their Digital Therapeutics.
CureApp and its “Digital Therapeutics︎︎”, together with NASH (Non-Alcoholic Steatohepatitis)have launched multi-center clinical trials of their Digital Therapeutics. CureApp Co., Ltd (head office: Chuo-ku, Tokyo, President and CEO: Kohta Satake) in collaboration with Koike Kazuhiko and Assistant Professor Masaya Sato from the Department of Gastroenterology and Internal Medicine at the University of Tokyo Hospital, have been carrying out the research and development of “Digital Therapeutics”. We are pleased to inform you that we are starting multiple institutional clinical trials of the (NASH App) Digital Therapeutics, an application dedicated to the treatment of NASH (Non-Alcoholic Steatohepatitis). This research follows the results of feasibility studies that have been conducted since 2016 at the University of Tokyo Hospital. It is a novel multi institutional clinical research project that has just begun and we aim to continue to obtain evidence to impro